Markets
paper Chinese yuan in piles
(Shutterstock)

The market wants more from China

The stock rally continued when China’s onshore market reopened, but traders were disappointed at the lack of further policies to save China’s sluggish economy

China’s market had an epic rally after China’s central bank unveiled a slew of monetary stimulus measures in September. 

A big question remained, though: how long will it last? We may have gotten some clues as the market reopened on Tuesday after a seven-day National Day holiday from October 1 to 7, as the policy-driven rally seemed to have lost some momentum. 

The CSI 300, which tracks the top 300 stocks traded on the Shanghai Stock Exchange and the Shenzhen Stock Exchange, surged nearly 11% during the market open on Tuesday. But the index eased some gains throughout the day to finish 6.1% up.

Meanwhile, Hong Kong’s benchmark index, Hang Seng, slumped 5.6% on Tuesday, wiping out all gains during the National Day holiday (the Hong Kong stock exchange was closed only on October 1).

The decline was partly due to a disappointing presser from China’s top economic planner. After late September’s stimulus — which included rate cuts, lower existing mortgage rates, lower required reserve ratio, and a 800-million-yuan liquidity support for the stock market — traders were expecting more details on fiscal stimulus from the government to get the economy back on track. That includes spending incentives, special bonds, and support for “new college graduates, migrant workers, the unemployed, elderly, and disabled,” analysts said.

But at its first post-holiday meeting, the National Development and Reform Commission (NDRC) “did not provide any more details around the shape and size of the fiscal support that has been announced,” Deutsche Bank analysts wrote in a note.

Wall Street was expecting somewhere between 2 trillion and 3 trillion yuan in fiscal packages. The NDRC, however, announced a modest 200 billion yuan (about $28.3 billion), 100 billion yuan of which was going to construction projects. 

Some China watchers said that the announcement wasn’t surprising, given how Chinese government agencies usually behave. NDRC’s main goal was likely not to meet the market where it was, but more to send a signal to top government officials about the intent to target the economy, notwithstanding concrete policies.

Still, the CSI 300 finished at another record high. ETFs that track China megacaps gained over 30% in the past month, outperforming the S&P 500.

The market vs. the economy

Broadly, analysts agree that the booming stock market doesn’t change the fundamentals of China’s economy, which has been on a downhill path since 2021. But degrees of optimism over the market rally differ. 

Goldman Sachs upgraded its call on Chinese offshore stocks (Chinese companies that trade in Hong Kong or the US) to overweight on October 7 and shifted its tactical preference from H-shares (that are traded in Hong Kong dollars) to A-shares (that are traded in Chinese yuan), saying in a note to clients that these stocks are more directly exposed to stock market stimulus and retail investors’ participation.

Indeed, the retail sentiment alone, independent of fiscal measures, was strong in China. State media reported a 4x to 6x surge in the number of new brokerage accounts, mostly from young people. ETF inflows and margin financing activities also rose. Shares of China’s brokerage software like Hithink Flush and East Money have more than doubled since September 23.

But others see the Chinese economy as a deeper problem. Adam Wolfe, emerging markets economist at Absolute Strategy Research, distinguished between the stimulus measures for the real economy and the stock market, calling the former “mostly incremental, small, and inconsequential,” while the latter was “new, unlimited, and significant.” 

Olivier d’Assier, Head of APAC, Investment Decision Research at SimCorp, said that China’s banking system is “teetering on the verge of collapse,” and the announced stimulus was not enough.

“It is $59 trillion in size and only $142 billion was announced to recapitalize it — compare this to a US banking system of $23.4 trillion, much better diversified than China’s, and where the Fed spent $475 billion to recapitalize it during the GFC,” he said.

“As for the market, this is a policy-driven rally. It won’t last and it won’t change the equation for investors — most of whom will not have bought at the bottom,” d’Assier added.

More Markets

See all Markets
markets

Trump administration says tariffs on Chinese semiconductor imports are coming... in 2027

After a year-long investigation into China’s tactics to bolster its domestic semiconductor industry, the US has determined that its practices are “unreasonable” and is going to do something about that in 18 months.

The Trump administration’s office of the US trade representative said today that it plans to impose tariffs on imports of Chinese semiconductors at a rate higher than 0% to be decided at least 30 days before June 23, 2027.

“China’s pursuit of its dominance goals has severely disadvantaged US companies, workers, and the U.S. economy generally through lessened competition and commercial opportunities and through the creation of economic security risks from dependencies and vulnerabilities,” per the USTR’s notice of action.

These levies, should they come to pass, would apply to silicon, diodes, transistors, and more.

US markets were completely unbothered by this revelation, likely because there is no immediate action against Chinese semi companies and therefore no disruption to business-as-usual. This represents a punting of a contentious matter, similar to how China delayed restrictions on rare earth shipments as part of a deal between Presidents Trump and Xi following their October meeting.

It’s another sign of a thaw in the US-China relations over the hot-button issue of semiconductors after President Trump gave Nvidia the go-ahead to sell its H200 chips to buyers in the world’s second-largest economy.

markets

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the company's history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world in which the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

markets

Novo Nordisk rallies after FDA weight loss pill approval

Novo Nordisk’s US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening.

Now the first pill of its kind to receive approval from the regulator, Novo’s Wegovy pill is expected to launch in the US in early January 2026, and awaits the European Medicines Agency and other regulatory authorities’ approval after submitting for review in the second half of 2025, per the company’s press release. The 1.5 milligram starting dose of the pill will be sold at an introductory price of $149 a month.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk.

The approval was based on Novo’s Oasis 4 trial, which found participants who took 25 milligram doses of Wegovy pills daily lost 16.6% of their body weight over a 64 week period.

The approval will give Novo — which lost more than 50% of its market cap this year after Eli Lilly took the crown in weekly US prescriptions for injectable weight-loss drugs with its product Zepbound — a first-mover advantage in the expanding market. Lilly, which is down some 1% in pre-market trading today, has said its own oral drug orforglipron could be approved by March 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.